Revenue Breakdown
Composition ()
No data
Revenue Streams
Champions Oncology Inc (CSBR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Pharmacology services, accounting for 93.7% of total sales, equivalent to $13.12M. Another important revenue stream is Other. Understanding this composition is critical for investors evaluating how CSBR navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Champions Oncology Inc maintains a gross margin of 51.70%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 1.23%, while the net margin is 1.58%. These profitability ratios, combined with a Return on Equity (ROE) of 102.70%, provide a clear picture of how effectively CSBR converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CSBR competes directly with industry leaders such as SEER and ANIX. With a market capitalization of $90.96M, it holds a significant position in the sector. When comparing efficiency, CSBR's gross margin of 51.70% stands against SEER's 51.20% and ANIX's N/A. Such benchmarking helps identify whether Champions Oncology Inc is trading at a premium or discount relative to its financial performance.
